Holen Sie sich die Stockscreener-App
188.63
1.26%
2.34
Handel nachbörslich:
188.63
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Resmed Inc Aktie (RMD) Neueste Nachrichten
Is ResMed (NYSE:RMD) Market Reset Creating New Interest? - Kalkine Media
Resmed Inc (RMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Resmed Inc (RMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
Is ResMed stock underperforming the Dow? - MSN
ResMed downgraded at Morgan Stanley on Philips re-entry and GLP-1 headwinds - MSN
Resmed Inc (RMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ResMed Is Near Its 52-Week Low Despite 21% EPS Growth: What the GLP-1 Fear Is Getting Wrong - TIKR.com
ResMed Loses Bull as Margin Outlook Moderates -- Market Talk - Moomoo
ResMed Inc (RMD) Stock Down 3.9% -- Now Undervalued? GF Score: 9 - GuruFocus
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
Why ResMed (RMD) Shares Are Falling Today - Yahoo Finance
ResMed (RMD) Faces Downgrade Amid Market Concerns - GuruFocus
ResMed Shares Fall After Morgan Stanley Downgrade - Moomoo
ResMed Inc. Stock 12‑Month Price Target Cut to $277.74, Implies 43% Upside - TradingView
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ResMed stock downgraded at Morgan Stanley (RMD:NYSE) - Seeking Alpha
Resmed Completes Acquisition of Noctrix Health - San Diego Business Journal
Morgan Stanley Downgrades ResMed(RMD.US) to Hold Rating, Cuts Target Price to $230 - Moomoo
Morgan Stanley downgrades ResMed stock rating on margin concerns - Investing.com
Morgan Stanley Downgrades ResMed to Equalweight From Overweight, Adjusts PT to $230 From $286 - marketscreener.com
Morgan Stanley downgrades ResMed stock rating on margin concerns By Investing.com - Investing.com UK
Analyst recommendations: Block, Resmed, Applied Materials, Ge Vernova, Intel… - marketscreener.com
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells? - MSN
Citigroup Adjusts Price Target on ResMed to $270 From $340, Maintains Buy Rating - marketscreener.com
ResMed Inc. (RMD) Stock Analysis: Exploring a Potential 38.93% Upside in the Healthcare Innovator - DirectorsTalk Interviews
ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
Landscape Capital Management L.L.C. Sells 32,899 Shares of ResMed Inc. $RMD - MarketBeat
ResMed added as new short idea at Hedgeye - MSN
ResMed Inc. Stock (US7611521078): Ownership moves after year-to-date pressure - AD HOC NEWS
Should you continue to hold Resmed stock in your portfolio? - MSN
Milford Funds Ltd. Makes New $28.42 Million Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Nutshell Asset Management Ltd's ResMed Inc(RMD) Holding History - GuruFocus
Why Are ResMed Shares Under Pressure Despite Solid Results? - Kalkine Media
Do Wall Street analysts like ResMed stock? - MSN
ResMed (RMD) Faces Potential 30% Decline Amid Market Concerns - GuruFocus
Is ResMed Inc. (RMD) A Good Stock To Buy Now? - Insider Monkey
Is ResMed Stock Underperforming the Dow? - Barchart.com
ResMed: GLP-1 Threats Are Overstated (NYSE:RMD) - Seeking Alpha
ResMed Inc. $RMD Shares Bought by Deutsche Bank AG - MarketBeat
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
Buy, hold, sell: Resmed, Goodman Group, Westpac shares - The Motley Fool Australia
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed chairman & CEO Michael Farrell sells $968k in stock By Investing.com - Investing.com Australia
ResMed chairman & CEO Michael Farrell sells $968k in stock - Investing.com Nigeria
ResMed Inc. stock (US7611521078): Sleep apnea specialist in focus after recent earnings update - AD HOC NEWS
ResMed (NYSE:RMD) CEO Sells $968,054.36 in Stock - MarketBeat
Resmed Insider Sold Shares Worth $968,064, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise - Stock Titan
Why ResMed Inc (RMD) Is Set to Outperform the Market: Insights i - GuruFocus
Is This the Right Time to Retain Resmed Stock in Your Portfolio? - Yahoo Finance
LGT Capital Partners LTD. Sells 25,752 Shares of ResMed Inc. $RMD - MarketBeat
BLI Banque de Luxembourg Investments Cuts Stake in ResMed Inc. $RMD - MarketBeat
Down 28% in a year, should I buy the dip on Resmed shares right now? - The Motley Fool Australia
1.32%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):